文献速递白血病造血干细胞移植与细胞治疗

可测量残留病、预处理方案强度与年龄预测首次缓解急性髓系白血病异基因造血干细胞移植结局:欧洲血液与骨髓移植学会急性白血病工作组2292例患者登记分析

Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
PubMed 文献 · Am J Hematol · 2018-08-15

该回顾性登记研究纳入2000-2015年接受异基因造血干细胞移植的2292例首次形态学完全缓解的急性髓系白血病患者,按年龄分层与可测量残留病状态比较清髓性与减低强度/非清髓预处理方案的结局。多变量分析显示,仅在<50岁且可测量残留病阳性组中,减低强度/非清髓预处理较清髓性预处理复发风险更高(HR 1.71)、无白血病生存更差(HR 1.554)。

要点

  • <50岁可测量残留病阳性患者应优先接受清髓性异基因造血干细胞移植。
  • <50岁可测量残留病阴性患者接受减低强度/非清髓移植后慢性移植物抗宿主病更少(HR 0.714)。
  • ≥50岁可测量残留病阳性患者需要新的治疗策略。

核心结论

  • <50岁且可测量残留病阳性的急性髓系白血病首次完全缓解患者应优先接受清髓性异基因造血干细胞移植。
  • 可测量残留病阴性患者能否免于清髓性方案毒性需前瞻性研究。
  • ≥50岁可测量残留病阳性患者需要新的方法。

研究设计与样本

  • 欧洲血液与骨髓移植学会登记库回顾性研究,纳入2000-2015年接受异基因造血干细胞移植的>18岁急性髓系白血病首次形态学完全缓解患者2292例。
  • 按年龄(<50岁或≥50岁)与可测量残留病状态配对分为四组,比较清髓性(MAC)与减低强度/非清髓(RIC/NMA)预处理方案。

主要发现

  • 多变量分析中,仅在<50岁可测量残留病阳性组,减低强度/非清髓预处理较清髓性预处理复发发生率更差(HR 1.71)、无白血病生存更差(HR 1.554)。
  • <50岁可测量残留病阴性患者接受减低强度/非清髓移植后慢性移植物抗宿主病更少(HR 0.714)。
  • 无移植物抗宿主病无复发生存在各组中均未受预处理强度显著影响。

关键数值与推荐

  • <50岁可测量残留病阳性:清髓性(N=240)vs 减低强度/非清髓(N=58),减低强度/非清髓组复发发生率HR 1.71、无白血病生存HR 1.554。
  • <50岁可测量残留病阴性:清髓性(N=665)vs 减低强度/非清髓(N=195),减低强度/非清髓组慢性移植物抗宿主病HR 0.714。
  • ≥50岁可测量残留病阳性:清髓性(N=126)vs 减低强度/非清髓(N=230)。
  • ≥50岁可测量残留病阴性:清髓性(N=223)vs 减低强度/非清髓(N=555)。

临床怎么用

  • 作者认为<50岁可测量残留病阳性急性髓系白血病首次完全缓解患者应优先接受清髓性异基因造血干细胞移植。
  • 作者建议需前瞻性研究探讨可测量残留病阴性患者能否免于清髓性方案毒性。
  • 作者提出≥50岁可测量残留病阳性患者需要新的方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with acute myeloid leukemia (AML) in morphological first complete remission (CR1) pre-allogeneic hematopoietic cell transplantation (HCT) may have measurable residual disease (MRD) by molecular and immunophenotyping criteria. We assessed interactions of MRD status with HCT conditioning regimen intensity in patients aged <50 years (y) or ≥50y. This was a retrospective study by the European Society for Blood and Marrow Transplantation registry. Patients were >18y with AML CR1 MRD NEG/POS and recipients of HCT in 2000-2015. Conditioning regimens were myeloablative (MAC), reduced intensity (RIC) or non-myeloablative (NMA). Outcomes included leukemia free survival (LFS), overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM), chronic graft-vs-host (cGVHD), and GVHD-free and relapse-free survival (GRFS). The 2292 eligible patients were categorized into four paired groups: <50y MRD POS MAC (N = 240) vs RIC/NMA (N = 58); <50y MRD NEG MAC (N = 665) vs RIC/NMA (N = 195); ≥50y MRD POS MAC (N = 126) vs RIC/NMA (N = 230), and ≥50y MRD NEG MAC (N = 223) vs RIC/NMA (N = 555). In multivariate analysis RIC/NMA was only inferior to MAC for patients in the <50y MRD POS group, with worse RI (HR 1.71) and LFS (HR 1.554). Patients <50Y MRD NEG had less cGVHD after RIC/NMA HCT (HR 0.714). GRFS was not significantly affected by conditioning intensity in any group. Patients aged <50y with AML CR1 MRD POS status should preferentially be offered MAC allo-HCT. Prospective studies are needed to address whether patients with AML CR1 MRD NEG may be spared the toxicity of MAC regimens. New approaches are needed for ≥50y AML CR1 MRD POS.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Gilleece MH, Labopin M, Yakoub-Agha I, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018. PMID: 29981272. doi:10.1002/ajh.25211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。